#CNSDisorders

Nucleic Acids Research

@narjournal.bsky.social

1 month ago

⭐NAR Breakthrough! ⭐
#RNAtherapeutics show strong promise for #CNSdisorders 🧠. #Preclinical studies reveal that very high doses of #oligonucleotides can cause brief, reversible neuronal activation driven by metal ion interactions 🧪.
Read the full article here: doi.org/10.1093/nar/...

AI News Brew

@ainewsbrew.bsky.social

8 months ago

Enveric Biosciences' EB-003 Shows Potential for Broader Neurological Treatment Applications | AI News Brew <p>CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics, has announced new data that expands the pote...

Enveric Biosciences' EB-003 Shows Potential for Broader Neurological Treatment Applications
ainewsbrew.com/article/4791

#EnvericBiosciences #EB003 #BiotechBreakthrough #NeurologicalTreatment #DrugDevelopment #CNSDisorders #MentalHealth #ParkinsonsResearch #MigraineTreatment #NASDAQNews

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

1 year ago

Dementia drug neflamapimod shows positive phase 2b trial results - PharmaTimes CervoMed's therapy demonstrates significant improvement in patients

#AlzheimersDisease #Dementia #neflamapimod #CNSdisorders #biotech #CervoMed #dementiapatients #RewinDLBstudy #dementiawithLewybodies #DLB #ClinicalDementiaRatingSumofBoxes #CDRSB #AlzheimersDiseaseCooperativeStudy #ClinicalGlobalImpressionofChange #CGIC
pharmatimes.com/news/dementi...

NASEM Health and Medicine

@health.nationalacademies.org

1 year ago

#GLP1R agonists show clinical promise in treating more than obesity and diabetes. In Sept 2024, we hosted a workshop exploring the potential for GLP-1 agonists to treat #CNSdisorders like substance use disorders, and more. Access the proceedings here: buff.ly/43fY2Tk

SynapCell

@synapcell.bsky.social

1 year ago

🌟 Accelerating Drug Discovery in CNS Disorders 🌟

Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together!

#DrugDiscovery #CNSdisorders #PreclinicalResearch

KStrategy&

@kstrategyand.bsky.social

1 year ago

Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments Noema Pharma, a clinical-stage biotech company focused on developing innovative treatments for central nervous system (CNS) disorders, has successfully closed an extension of its Series B financing ro...

www.linkedin.com/pulse/noema-...

Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments

kstrategyand.com/pharma-news

#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

1 year ago

Neuraxpharm and Pharmathen partner to develop long-acting injectable therapies - Pf Media Neuraxpharm and Pharmathen have announced a strategic alliance to co-develop new long-acting injectable therapies.

#mentalhealth #CNSdisorders #Neuraxpharm #Pharmathen #longactinginjectabletherapies #LATT #psychiatry #LATTprogram #shortactingdosageforms #prescribers #patientcompliance #LAI #LAIproducts #CNSproducts #CNSpatients #establishedtherapies #patientchoice
pf-media.co.uk/news/neuraxp...

@carloslarrauri.bsky.social

3 years ago

ow.ly ow.ly

Join @NASEM_Health’s #NeuroForum on March 13-14 for a workshop exploring how psychiatry, pediatric neurology, and neurodevelopmental disorders are progressing multimodal biomarker generation. Register: http://ow.ly/zSEF50MBq2f #CNSDisorders